

FATP1-IN-1 biochemical

FATP1-IN-1

CATALOG #
AAA227707

PRODUCT SYNONYMS

FATP1-IN-1; FATP1-IN-1 biochemical

PRODUCT SPECIFICATIONS

Purity/Purification	98%
CAS	1431945-95-7
Solubility	<1mg/ml refers to the product slightly soluble or insoluble
In vitro	FATP1-IN-1 (p.o.; 10 mg/kg) treatment shows the C max, AUC and T max were 5.5 ug/mL, 36 ug h/mL and 0.33 hours, respectively, and exceeds the mouse IC 50 value of 0.22 uM without considering plasma protein binding. Animal Model: Mouse plasma[1]. Dosage: 10 mg/kg. Administration: P.o. Result: The C max, AUC and T max were 5.5 ug/mL, 36 ug h/mL and 0.33 hours, respectively.
Preparation and Storage	Powder: -20 degree C for 3 years In solvent: -80 degree C for 2 years

IMAGES


Structure

C-Type Natriuretic Peptide (CNP)(1-22), human TFA, CAS 1966153-17-2


Structure

C-Type Natriuretic Peptide (CNP)(1-22), human TFA, CAS 1966153-17-2

ADDITIONAL INFORMATION

Related Product Information for FATP1-IN-1 biochemical	FATP1-IN-1 is a fatty acid transport protein 1 (FATP1) inhibitor. FATP1-IN-1 is an inhibition of recombinant human or mouse acyl-CoA synthetase activity of FATP1, with the IC 50 values of 0.046 uM or 0.60 uM, respectively.
References	- Morozumi N, et al. ASB20123: A novel C-type natriuretic peptide derivative for treatment of growth failure and dwarfism. PLoS One. 2019 Feb 22;14(2):e0212680. - Mazarati AM, et al. ANP(1-28), BNP(1-32) and CNP(1-22) increase the severity of picrotoxin-kindled seizure syndrome in rats. Life Sci. 1993;52(3):PL19-24.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.

